Title:
薬物中毒および他の障害の治療のための遺伝子組み換え大麻植物および組み換えカンナビノイド化合物
Document Type and Number:
Japanese Patent JP7322353
Kind Code:
B2
Abstract:
A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.
Inventors:
Williams, Johnny Earl.
Application Number:
JP2021070269A
Publication Date:
August 08, 2023
Filing Date:
April 19, 2021
Export Citation:
Assignee:
MyMD Pharmaceuticals, Inc.
International Classes:
C07D311/78; A61K9/08; A61K9/10; A61K9/107; A61K9/127; A61K9/16; A61K9/20; A61K9/48; A61K31/352; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/34; A61P25/36
Domestic Patent References:
| JP2018504407A | ||||
| JP2009538893A |
Foreign References:
| WO2017011210A1 | ||||
| WO2014039042A1 |
Attorney, Agent or Firm:
Patent Attorney Corporation RYUKA International Patent Office